Literature DB >> 18486420

Arginase blockade lessens endothelial dysfunction after thrombosis.

Chandani Lewis1, Weifei Zhu, Mircea L Pavkov, Corttrell M Kinney, Paul E Dicorleto, Vikram S Kashyap.   

Abstract

INTRODUCTION: Acute arterial thrombosis causes endothelial dysfunction due to decreased nitric oxide bioactivity. Increased arginase activity may modulate intracellular L-arginine levels, the substrate for nitric oxide. The purpose of this study was to identify the role of arginase in endothelial dysfunction in cell culture and in the vasomotor response of arteries exposed to thrombus.
METHODS: Rat aortic endothelial cells were exposed to thrombin at different time points. The cell extract was analyzed by immunoblotting and real-time polymerase chain reaction. Adult male rats underwent infrarenal aortic thrombosis by clip ligature for 1 hour. Infrarenal aortic ring segments were harvested and placed in physiologic buffer baths, and a force transducer was used to measure endothelial-dependent relaxation (EDR) and endothelial-independent relaxation (EIR). Arginase blockade was performed by incubating infrarenal aortic ring segments with arginase inhibitors for 1 hour before measuring EDR. Whole tissue extracts also underwent immunoblot analysis. The EDR and EIR curves were compared with analyses of variance.
RESULTS: A 6.76 +/- 1.4-fold induction in arginase I message levels (P = .001) was found in rat aortic endothelial cells exposed to thrombin (30 U/mL), and arginase I protein levels increased 2.1 times. The eight infrarenal aortic ring segments exposed to thrombosis for 1 hour had diminished EDR curves compared with 14 nonthrombosed normal segments (controls). The maximum (+/- SEM) EDR (acetylcholine 10(-5)M dose) in control infrarenal aortic ring segments was 108% +/- 4.3% compared with 63% +/- 6.2% for thrombosed infrarenal aortic ring segments (P < .001). Exposure to arterial thrombosis resulted in a 3.8-times increase in arginase I protein levels in infrarenal aortic ring segments. Preincubation of nine infrarenal aortic ring segments with the nonspecific (difluoromethylornithine) and six with specific ([S]-[2-boronoethyl]-L-Cysteine-HCl [BEC]) arginase inhibitor for 1 hour significantly increased the maximum EDR compared with untreated thrombosed segments (104 +/- 5.2, 108 +/- 7.6 vs 63% +/- 6.2, P < .001). EDR curves for difluoromethylornithine- and BEC-treated infrarenal aortic ring segments were superimposed on control EDR curves. The EIR and the vasoconstriction with norepinephrine for all groups were similar.
CONCLUSION: Endothelial cells exposed to thrombin have increased arginase I messenger RNA and protein levels. Arterial thrombosis causes endothelial dysfunction without affecting smooth muscle responsiveness. Arginase blockade can lead to normalization of arterial vasomotor function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18486420      PMCID: PMC2517129          DOI: 10.1016/j.jvs.2008.02.030

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  22 in total

1.  Arginase pathway in human endothelial cells in pathophysiological conditions.

Authors:  Tiziana Bachetti; Laura Comini; Gloria Francolini; Daniela Bastianon; Barbara Valetti; Moris Cadei; PierGiovanni Grigolato; Hisanori Suzuki; Dario Finazzi; Alberto Albertini; Salvatore Curello; Roberto Ferrari
Journal:  J Mol Cell Cardiol       Date:  2004-08       Impact factor: 5.000

2.  Acute arterial thrombosis causes endothelial dysfunction: a new paradigm for thrombolytic therapy.

Authors:  V S Kashyap; T D Reil; W S Moore; T X Hoang; H A Gelabert; R E Byrns; L J Ignarro; J A Freischlag
Journal:  J Vasc Surg       Date:  2001-08       Impact factor: 4.268

3.  Endothelial dysfunction after arterial thrombosis is ameliorated by L-arginine in combination with thrombolysis.

Authors:  Michael R Davis; Delio P Ortegon; Jeffrey D Kerby; Louis J Ignarro; Vikram S Kashyap
Journal:  J Vasc Interv Radiol       Date:  2003-02       Impact factor: 3.464

4.  The effects of thrombus, thrombectomy and thrombolysis on endothelial function.

Authors:  T D Reil; W S Moore; V S Kashyap; S S Nene; H A Gelabert; W J Quinones-Baldrich
Journal:  Eur J Vasc Endovasc Surg       Date:  2000-02       Impact factor: 7.069

5.  Luminal thrombus disrupts nitric oxide-dependent endothelial physiology.

Authors:  Michael R Davis; Delio P Ortegon; William D Clouse; Jeffrey D Kerby; Jeffrey D DeCaprio; Andy Chiou; Ryan T Hagino; Vikram S Kashyap
Journal:  J Surg Res       Date:  2002-05-15       Impact factor: 2.192

6.  Arginase activity in endothelial cells: inhibition by NG-hydroxy-L-arginine during high-output NO production.

Authors:  G M Buga; R Singh; S Pervin; N E Rogers; D A Schmitz; C P Jenkinson; S D Cederbaum; L J Ignarro
Journal:  Am J Physiol       Date:  1996-11

7.  L-arginine improves endothelial vasoreactivity and reduces thrombogenicity after thrombolysis in experimental deep venous thrombosis.

Authors:  Peter H Lin; Chris K Johnson; Jennifer K Pullium; Ruth L Bush; Brian S Conklin; Changyi Chen; Alan B Lumsden
Journal:  J Vasc Surg       Date:  2003-12       Impact factor: 4.268

8.  Arginase reciprocally regulates nitric oxide synthase activity and contributes to endothelial dysfunction in aging blood vessels.

Authors:  Dan E Berkowitz; Ron White; Dechun Li; Khalid M Minhas; Amy Cernetich; Soonyul Kim; Sean Burke; Artin A Shoukas; Daniel Nyhan; Hunter C Champion; Joshua M Hare
Journal:  Circulation       Date:  2003-09-29       Impact factor: 29.690

9.  Regulation of endothelial nitric oxide synthase by the actin cytoskeleton.

Authors:  Yunchao Su; Sophia Edwards-Bennett; Michael R Bubb; Edward R Block
Journal:  Am J Physiol Cell Physiol       Date:  2003-01-29       Impact factor: 4.249

Review 10.  Arginine metabolism: nitric oxide and beyond.

Authors:  G Wu; S M Morris
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

View more
  7 in total

Review 1.  Recent advances in arginine metabolism: roles and regulation of the arginases.

Authors:  Sidney M Morris
Journal:  Br J Pharmacol       Date:  2009-06-05       Impact factor: 8.739

Review 2.  Pharmacokinetics and Pharmacodynamics of Promising Arginase Inhibitors.

Authors:  Khaled S Abdelkawy; Kelsey Lack; Fawzy Elbarbry
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-06       Impact factor: 2.441

3.  Techniques to harvest diseased human peripheral arteries and measure endothelial function in an ex vivo model.

Authors:  Ryan O Lakin; Weifei Zhu; Lindsay Feiten; Vikram S Kashyap
Journal:  J Vasc Surg       Date:  2013-02-01       Impact factor: 4.268

4.  The vascular effects of different arginase inhibitors in rat isolated aorta and mesenteric arteries.

Authors:  N N Huynh; E E Harris; J F P Chin-Dusting; K L Andrews
Journal:  Br J Pharmacol       Date:  2009-01       Impact factor: 8.739

5.  Thrombin induces endothelial arginase through AP-1 activation.

Authors:  Weifei Zhu; Unni M Chandrasekharan; Smarajit Bandyopadhyay; Sidney M Morris; Paul E DiCorleto; Vikram S Kashyap
Journal:  Am J Physiol Cell Physiol       Date:  2009-12-23       Impact factor: 4.249

Review 6.  Arginase as a Potential Biomarker of Disease Progression: A Molecular Imaging Perspective.

Authors:  Gonçalo S Clemente; Aren van Waarde; Inês F Antunes; Alexander Dömling; Philip H Elsinga
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

Review 7.  Targeting Arginine in COVID-19-Induced Immunopathology and Vasculopathy.

Authors:  William Durante
Journal:  Metabolites       Date:  2022-03-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.